Adverse Effect Management in EGFR+ NSCLC

Narjust Florez, MD, and Stephanie J. McDonald, MSN, FNP-BC, AOCNP, review common toxicities associated with EGFR-targeted therapies and approaches to management in EGFR-mutated non–small cell lung cancer. Florez discusses dermatologic, gastrointestinal, and pulmonary adverse events that require prompt recognition and intervention to prevent treatment interruptions. McDonald emphasizes proactive monitoring, patient education, and supportive care measures to maintain dose intensity and quality of life.